Berry Oncology Releases Latest Research Results on Early Screening for Multiple Cancers
PR92296
SHANGHAI, Oct. 13, 2021 /PRNewswire=KYODO JBN/ --
-Head of the Chinese oncology genomic testing company shared their recent
findings on early screening for multiple high-risk cancers
Berry Oncology, a Chinese oncology genomic testing company, was invited to the
inaugural International Biopharma Industry Week in Shanghai (IBIWS) running
from October 11-14, where CEO Jun Zhou delivered a much-anticipated keynote
speech at the "2021 Future Healthcare Industry Summit" subforum, unveiling the
company's latest research results on early screening for multiple cancers.
The advanced results of the study cover a higher proportion of early-stage
patients: 73% of stage I and II samples overall, and 69.6% and 92.9%
sensitivity in stage I and II samples respectively, which significantly
outperforms data models of other top-tier international companies of its kind.
With the HIFI method, a liquid biopsy, platform-based technology developed by
Berry Oncology, a single test can early screen for six major high-risk cancers
in China, including liver, lung, gastric, colorectal, esophageal and pancreatic
cancers, with an overall sensitivity of 87.6%, specificity of 99.1% and overall
TOO (Tissue of Origin) precision in 82% of positive cancers, elevating test
performance to an advanced international level.
Jun Zhou said, "In this multi-cancer early screening study, Berry Oncology
specifically chose lung and gastrointestinal cancers as the breakthrough point
as they pose the highest threat in terms of morbidity and mortality in China.
From the outset of our product design, we specifically took into account the
tumorigenic characteristics of the Chinese population and which cancer most
urgently needs early screening solutions."
Notably, the detection of pancreatic cancer, one of the most challenging and
malignant of cancers, has once again demonstrated the extraordinary performance
of Berry Oncology's early screening technology, with a sensitivity and
specificity of over 90% and an area under the curve (AUC) of 0.975.
As one of the earliest Chinese companies engaged in the early screening of
cancers, Berry Oncology is the first to apply its self-developed HIFI method to
the early screening of liver and lung cancers. At CSCO 2021, Berry Oncology
announced the results of a pilot study on early screening of lung cancer, in
which HIFI technology was validated with an AUC of 0.912 in a sample cohort
that better matches the characteristics of Chinese patients, with 80.9% of
stage I lung cancers and 89.2% of lung adenocarcinomas.
Visit Berry Oncology.
SOURCE:Berry Oncology
Image Attachments Links:
Link: http://asianetnews.net/view-attachment?attach-id=403797
Caption: Berry Oncology
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。